Genelux Corporation (GNLX) vs TuHURA Biosciences, Inc. (HURA)
A side-by-side comparison of Genelux Corporation and TuHURA Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.62HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT
HURA
TuHURA Biosciences, Inc.
$1.90HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Total return — GNLX vs HURA
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)HURA -69.1% (-25.5%/yr)GNLX compounded faster over this window
GNLX HURA
GNLX vs HURA: by the numbers
- •HURA is the larger company ($121M vs $118M market cap).
- •Both run net losses; HURA's is the smaller (0.00% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | HURA |
|---|---|---|
| P/S ratio | 14692.52 | N/A |
| P/B ratio | 7.29 | 6.62 |
Profitability
| Metric | GNLX | HURA |
|---|---|---|
| Gross margin | -7075.00% | 0.00% |
| Operating margin | -415175.00% | 0.00% |
| Net margin | -422412.50% | 0.00% |
| ROE | -209.73% | -165.57% |
| ROIC | -192.18% | -137.40% |
Growth (annualized)
| Metric | GNLX | HURA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -45.49% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.